DAWN Day One Biopharmaceuticals, Inc.
USHealthcareAs of 2026-04-24 09:30
Why DAWN matters now
Day One Biopharmaceuticals, Inc. (DAWN) is a US stock in Healthcare. The latest InvestLog snapshot shows $21.53 with +0.00% on the session and $2.22B in market capitalization; recent performance reads 1-month +0.00% and YTD +131.01%.
The latest financial table shown here is Q4 2025, with revenue of $53.7M, net income of $-21.3M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.8%.
The latest indexable market news headline is "Servier completes the acquisition of Day One Biopharmaceuticals" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $21.50; recent insider activity includes AI Day1 LLC filing D-Return. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.05
P/S
14.06
EV/EBITDA
-19.24
DCF Value
$55.67
FCF Yield
-4.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.1%
Operating Margin
-80.8%
Net Margin
-67.8%
ROE
-23.4%
ROA
-21.1%
ROIC
-28.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $53.7M | $-21.3M | $-0.21 |
| FY 2025 | $158.2M | $-107.3M | $-1.04 |
| Q3 2025 | $39.8M | $-19.7M | $-0.19 |
| Q2 2025 | $33.9M | $-30.3M | $-0.29 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$21.50
Target (Median)
$21.50
Target Range
$21.50 - $21.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-1.75
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.